Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

By Oliver Hirt ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in ...

Generic drugmaker Sandoz (OTCQX:SDZXF) announced on Monday the filing of an antitrust lawsuit alleging that Amgen ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

After accumulating $86 billion in global sales, Amgen is still trying to keep Enbrel biosimilars off the market, Sandoz ...

Sandoz (SDZNY) announced the filing of an antitrust lawsuit in the U.S. against Amgen (AMGN), for extending and entrenching the dominant market ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs deemed unaffordable in Colorado, finding that the maker of arthritis ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Pharmaceutical company Sandoz has filed a federal lawsuit accusing Amgen of orchestrating an illegal scheme to block biosimilar competition for its blockbuster arthritis drug Enbrel, resulting in ...